Daiwa Securities Group Inc. Avadel Pharmaceuticals PLC Transaction History

Daiwa Securities Group Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 02, 2024	BUY	$12.55 - $17.22 $1,091 - $1,498	87 Added 35.51%	332 $6,000
Q4 2022 Feb 06, 2023	BUY	$5.02 - $10.0 $627 - $1,250	125 Added 104.17%	245 $2,000
Q4 2020 Feb 04, 2021	BUY	$5.03 - $7.95 $603 - $954	120 New	120 $1,000
Q2 2020 Aug 11, 2020	SELL	$7.25 - $11.75 $334,225 - $541,675	-46,100 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$4.06 - $10.64 $187,165 - $490,504	46,100 New	46,100 $366,000
Q4 2018 Feb 05, 2019	SELL	$1.74 - $4.66 $394 - $1,057	-227 Closed	0 $0
Q1 2018 May 02, 2018	BUY	$6.76 - $11.7 $1,534 - $2,655	227 New	227 $2,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

Stay updated on Daiwa Securities Group Inc. with notifications on news.